menu search

AVTE / Aerovate: Developing An Exciting PAH Drug, Initiating With A Buy

Aerovate: Developing An Exciting PAH Drug, Initiating With A Buy
Aerovate is a SMID-cap biotech developing an inhaled imatinib for pulmonary arterial hypertension. AV-101's Phase 2b PAH data is expected in 4Q 2023 or 1Q 2024, which we believe will be positive. Read More
Posted: Jan 29 2023, 07:12
Author Name: Seeking Alpha
Views: 110420

AVTE News  

Aerovate: Small Mid-Stage Biotech Targeting Multibillion-Dollar PAH Market

By Seeking Alpha
April 12, 2023

Aerovate: Small Mid-Stage Biotech Targeting Multibillion-Dollar PAH Market

AVTE reported Q4 2023 earnings in line with expectations and has enough cash runway until H2 2025. AV-101, AVTE's lead asset, is on track with patient more_horizontal

Aerovate: Developing An Exciting PAH Drug, Initiating With A Buy

By Seeking Alpha
January 29, 2023

Aerovate: Developing An Exciting PAH Drug, Initiating With A Buy

Aerovate is a SMID-cap biotech developing an inhaled imatinib for pulmonary arterial hypertension. AV-101's Phase 2b PAH data is expected in 4Q 2023 o more_horizontal


Search within

Pages Search Results: